{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:02:58Z","timestamp":1762506178648},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Portuguese Science and Technology Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ejca.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T13:48:25Z","timestamp":1380548905000},"page":"359-365","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration"],"prefix":"10.1016","volume":"50","author":[{"given":"Avelino","family":"Fraga","sequence":"first","affiliation":[]},{"given":"Ricardo","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Pr\u00edncipe","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lobato","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Pina","sequence":"additional","affiliation":[]},{"given":"Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[]},{"given":"C\u00e1tia","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"F.","family":"Calais da Silva","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2013.09.001_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.ejca.2013.09.001_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/gm166","article-title":"Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?","volume":"2","author":"Wiklund","year":"2010","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.ejca.2013.09.001_b0015","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1073\/pnas.0914061107","article-title":"Inherited genetic variant predisposes to aggressive but not indolent prostate cancer","volume":"107","author":"Xu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.ejca.2013.09.001_b0020","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1158\/1078-0432.CCR-07-5119","article-title":"Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients","volume":"14","author":"Teixeira","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2013.09.001_b0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/tpj.2009.20","article-title":"Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility","volume":"9","author":"Teixeira","year":"2009","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.ejca.2013.09.001_b0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1158\/1055-9965.EPI-08-1148","article-title":"Established prostate cancer susceptibility variants are not associated with disease outcome","volume":"18","author":"Wiklund","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.001_b0035","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/0008-5472.CAN-08-2343","article-title":"Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk","volume":"69","author":"Wright","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.001_b0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.urology.2011.01.061","article-title":"Validation of postoperative nomograms in prostate cancer patients with long-term follow-up","volume":"78","author":"Swanson","year":"2011","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.ejca.2013.09.001_b0045","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa075819","article-title":"Cumulative association of five genetic variants with prostate cancer","volume":"358","author":"Zheng","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2013.09.001_b0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0210-4806(09)72891-8","article-title":"Tumor hypoxia: the role of HIF","volume":"33","author":"Fraga","year":"2009","journal-title":"Actas Urol Esp"},{"issue":"2","key":"10.1016\/j.ejca.2013.09.001_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semradonc.2008.12.002","article-title":"Cancer stem cells, hypoxia and metastasis","volume":"19","author":"Hill","year":"2009","journal-title":"Semin Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2013.09.001_b0060","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/carcin\/bgg132","article-title":"Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance","volume":"24","author":"Tanimoto","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2013.09.001_b0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.001_b0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.urolonc.2007.12.001","article-title":"Clinical implications of hypoxia inducible factor in renal cell carcinoma","volume":"27","author":"Smaldone","year":"2009","journal-title":"Urol Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2013.09.001_b0075","first-page":"5830","article-title":"Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases","volume":"59","author":"Zhong","year":"1999","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2013.09.001_b0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4161\/cbt.8.2.7086","article-title":"The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers","volume":"8","author":"Foley","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2013.09.001_b0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1756-9966-28-159","article-title":"Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis","volume":"28","author":"Zhao","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2013.09.001_b0090","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4161\/cbt.4.11.2091","article-title":"Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer","volume":"4","author":"Chau","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"10.1016\/j.ejca.2013.09.001_b0095","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/pros.20589","article-title":"Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer","volume":"67","author":"Li","year":"2007","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ejca.2013.09.001_b0100","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2013.09.001_b0105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.001_b0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"European association of urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.001_b0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1677\/erc.1.00728","article-title":"Hypoxia-inducible factor-1 in human breast and prostate cancer","volume":"13","author":"Kimbro","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2013.09.001_b0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cdp.2003.12.009","article-title":"Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis","volume":"28","author":"Zhong","year":"2004","journal-title":"Cancer Detect Prev"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.001_b0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11934-002-0068-6","article-title":"Tumor hypoxia and the progression of prostate cancer","volume":"3","author":"Anastasiadis","year":"2002","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ejca.2013.09.001_b0130","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/aja.2012.101","article-title":"Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population","volume":"14","author":"Li","year":"2012","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.001_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pros.20433","article-title":"The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer","volume":"67","author":"Orr-Urtreger","year":"2007","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ejca.2013.09.001_b0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pros.20190","article-title":"Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation","volume":"63","author":"Fu","year":"2005","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.ejca.2013.09.001_b0145","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cbt.20554","article-title":"HIF1A C1772T polymorphism leads to HIF-1\u03b1 mRNA overexpression in prostate cancer patients","volume":"13","author":"Vainrib","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2013.09.001_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054251","article-title":"The role of hypoxia-inducible factor 1a in determining the properties of castrate-resistant prostate cancers","volume":"8","author":"Ranasinghe","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejca.2013.09.001_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2012.03.022","article-title":"The role of hypoxia-inducible factor-1alpha and -2alpha in androgen insensitive prostate cancer cells","author":"Jeong","year":"2013","journal-title":"Urol Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2013.09.001_b0160","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/0008-5472.CAN-10-3320","article-title":"HIF induces human embryonic stem cell markers in cancer cells","volume":"71","author":"Mathieu","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2013.09.001_b0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2011.04.027","article-title":"Impact of hypoxia on the metastatic potential of human prostate cancer cells","volume":"81","author":"Dai","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"101","key":"10.1016\/j.ejca.2013.09.001_b0170","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.bjc.6605322","article-title":"Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer","volume":"2009","author":"Bratt","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.09.001_b0175","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, doubleblind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2013.09.001_b0180","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/pros.21495","article-title":"Leanderson T Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)","volume":"72","author":"Jennbacken","year":"2012","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.ejca.2013.09.001_b0185","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1021\/mp300193f","article-title":"Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth","volume":"9","author":"Liu","year":"2012","journal-title":"Mol Pharm"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913008253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913008253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T14:23:32Z","timestamp":1539354212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913008253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0959804913008253"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.09.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}